Biotech RadarJobs updated

COMPANY

Vir Biotechnology

HQ: San Francisco, CA source · vir.bio ↗ · West Coast

Clinical Phase 3

17 open jobs · last seen Oct 23, 2026 · 23 sources

Keywords: antibody immunology COVID-19 Ebola virus disease oncology infectious disease Viral Hepatitis Chronic Hepatitis B Covid19 Influenza A Hepatic Impairment Cirrhosis Locally Advanced or Metastatic HER2-Expressing Cancers Chronic Hepatitis D Solid Tumor Malignancies EGFR Positive Solid Tumors Renal Impairment HIV I Infection VIR-2218 VIR-3434 VIR-5818 VIR-5525 VIR-2482 VIR-1111 Sotrovimab VIR-7831 (sotrovimab)

Location: San Francisco, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

17Open jobs22Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Director, Clinical Operations OncologySan Francisco, California, United StatesOct 22, 2026Oct 23, 2026
Senior Director, Head of Clinical PharmacologyRemote - United StatesOct 15, 2026Oct 16, 2026
SVP, Regulatory AffairsSan Francisco, California, United StatesOct 13, 2026Oct 14, 2026
Director, Clinical ContractsSan Francisco, California, United StatesOct 12, 2026Oct 12, 2026
Senior Director, Total Rewards and HRISSan Francisco, California, United StatesOct 1, 2026Oct 8, 2026

See all 17 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (17 open jobs at last check). source ↗
  2. Partnership Partnership / licensing: upfront not published; stated deal value €55M (kept separate from upfront), announced Dec 16, 2025. Source: SEC filing. source ↗
  3. Trial start Phase 2: A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection source ↗
  4. Trial start Phase 3: A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide source ↗
  5. Trial start Phase 1: Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors source ↗
  6. Trial start Phase 3: A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection source ↗
  7. Trial start Phase 1: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 source ↗
  8. Trial start Phase 1/Phase 2: A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection source ↗
  9. Trial start 2: A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A source ↗
  10. Trial start Phase 1: Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 source ↗
  11. Trial start Phase 2: SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. source ↗
  12. Trial start Phase 1/Phase 2: To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-E source ↗
  13. Trial start Phase 1: Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) source ↗
  14. Trial start Phase 2: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection source ↗
  15. Trial start Phase 1: A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants source ↗
  16. Trial start Phase 3: Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. source ↗
  17. Trial start Phase 2: Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 source ↗
  18. Trial start Phase 1: VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers source ↗
  19. Trial start Phase 2/Phase 3: VIR-7831 for the Early Treatment of COVID-19 in Outpatients source ↗
  20. Trial start Phase 2: Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection source ↗
  21. Trial start Phase 1: Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection source ↗
  22. Trial start Phase 1: Study of VIR-2482 in Healthy Volunteers source ↗
  23. Trial start Phase 1/Phase 2: Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 17

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Director, Clinical Operations OncologySan Francisco, California, United StatesOct 22, 2026Oct 23, 2026Not stated
Senior Director, Head of Clinical PharmacologyRemote - United StatesOct 15, 2026Oct 16, 2026Not stated
SVP, Regulatory AffairsSan Francisco, California, United StatesOct 13, 2026Oct 14, 2026Executive
Director, Clinical ContractsSan Francisco, California, United StatesOct 12, 2026Oct 12, 2026Senior
Senior Director, Total Rewards and HRISSan Francisco, California, United StatesOct 1, 2026Oct 8, 2026Senior
Senior Director, Clinical Research-Program Executive-OncologySan Francisco, California, United StatesSep 28, 2026Oct 8, 2026Senior
Director, Clinical OperationsSan Francisco, California, United StatesSep 28, 2026Oct 8, 2026Senior
Associate Director, Clinical ScientistSan Francisco, California, United StatesSep 28, 2026Oct 8, 2026Senior
Associate Director, CMC Project ManagementSan Francisco, California, United StatesSep 21, 2026Oct 8, 2026Senior
Associate Director, Quality Systems (Temporary)San Francisco, California, United StatesSep 18, 2026Oct 8, 2026Senior
Senior Specialist, QA Operations (Temporary)San Francisco, California, United StatesSep 16, 2026Oct 8, 2026Senior
Senior Scientist I, Drug Product & Device Development (Temporary)San Francisco, California, United StatesSep 16, 2026Oct 8, 2026Senior
Scientist I, Analytical Development - Protein Chemistry (Temporary)San Francisco, California, United StatesSep 16, 2026Oct 8, 2026Entry
Scientist I, Stability (Temporary)San Francisco, California, United StatesSep 16, 2026Oct 8, 2026Entry
Senior IT Security & Infrastructure Engineer (Temporary)San Francisco, California, United StatesSep 15, 2026Oct 8, 2026Senior
Associate Director, Research Project ManagementSan Francisco, California, United StatesAug 3, 2026Oct 8, 2026Senior
Director, ToxicologySan Francisco, California, United StatesJul 20, 2026Oct 8, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Last 2 years.

Clinical trials (lead sponsor) 22

RecordTitlePhaseStatusStartPrimary completion
NCT05484206Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434Phase 1CompletedSep 21, 2022Dec 9, 2025 (actual)
NCT05356741To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing CancersPhase 1/Phase 2RecruitingApr 13, 20222028-04 (estimated)
NCT07128550A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtidePhase 3Active, not recruitingJul 30, 20252026-12 (estimated)
NCT05461170SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.Phase 2Active, not recruitingSep 17, 20222031-11 (estimated)
NCT04856085Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionPhase 2CompletedJul 11, 2021Mar 16, 2026 (actual)
NCT04412863Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionPhase 2CompletedJul 3, 2020Mar 25, 2024 (actual)
NCT06960395Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsPhase 1RecruitingJul 22, 20252029-08 (estimated)
NCT06903338A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionPhase 3Active, not recruitingMar 12, 2025Dec 31, 2026 (estimated)
NCT05612581A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B InfectionPhase 1/Phase 2CompletedMay 10, 2023Oct 15, 2024 (actual)
NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionPhase 2Active, not recruitingAug 5, 20252026-11 (estimated)
NCT05844228A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218Phase 1CompletedJun 1, 2023Mar 1, 2025 (actual)
NCT04423393Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus InfectionPhase 1CompletedMay 26, 2020Oct 24, 2022 (actual)
NCT05280717Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)Phase 1TerminatedMar 28, 2022Apr 5, 2023 (actual)
NCT05567783A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A2TerminatedOct 30, 2022May 5, 2023 (actual)
NCT04988152A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian ParticipantsPhase 1CompletedJul 6, 2021Sep 2, 2021 (actual)
NCT04913675Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.Phase 3TerminatedJun 10, 2021Jul 19, 2022 (actual)
NCT04779879Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19Phase 2CompletedFeb 18, 2021Aug 20, 2021 (actual)
NCT04725877VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy VolunteersPhase 1CompletedDec 28, 2020Dec 5, 2022 (actual)
NCT05235347Sotrovimab Expanded Access Treatment Protocol (COVID-19)Not listedNo longer availableNot listedNot listed
NCT04545060VIR-7831 for the Early Treatment of COVID-19 in OutpatientsPhase 2/Phase 3CompletedAug 27, 2020Apr 8, 2021 (actual)
NCT04033406Study of VIR-2482 in Healthy VolunteersPhase 1CompletedAug 26, 2019Nov 1, 2021 (actual)
NCT03672188Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis BPhase 1/Phase 2CompletedNov 14, 2018Sep 3, 2020 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Vir Biotechnology on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback